Fingolimod leads to early clinical and MRI benefits in relapsing-remitting multiple sclerosis

被引：0
|
作者：
Chin, P.
von Rosenstiel, P.
Haering, D.
Francis, G.
Kappos, L.
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
[2] Novartis Pharma AG, Basel, Switzerland
[3] Univ Basel Hosp, CH-4031 Basel, Switzerland
来源：
JOURNAL OF NEUROLOGY | 2012年 / 259卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S70 / S71
页数：2
相关论文
共 50 条
  • [31] Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod
    Gasperini, Claudio
    Ruggieri, Serena
    Mancinelli, Chiara Rosa
    Pozzilli, Carlo
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2013, 9 : 73 - 85
  • [32] The effect of cladribine versus fingolimod on clinical and MRI measures in relapsing remitting multiple sclerosis
    Cellerino, M.
    Sirito, T.
    Schiavi, S.
    Tazza, F.
    Pierella, C.
    Boccia, D.
    Mancuso, E.
    Boffa, G.
    Capello, E.
    Lapucci, C.
    Inglese, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 850 - 850
  • [33] MRI techniques and cognitive impairment in the early phase of relapsing-remitting multiple sclerosis
    R. Zivadinov
    R. De Masi
    D. Nasuelli
    L. Monti Bragadin
    M. Ukmar
    R. S. Pozzi-Mucelli
    A. Grop
    G. Cazzato
    M. Zorzon
    Neuroradiology, 2001, 43 : 272 - 278
  • [34] Relapsing-remitting multiple sclerosis
    Flores, A
    Ochoa, E
    Zamora, S
    Barrientos, UN
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 214 (1-2) : 110 - 110
  • [35] The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis
    Valis, Martin
    Achiron, Anat
    Hartung, Hans Peter
    Mares, Jan
    Ticha, Veronika
    Stourac, Pavel
    Haluskova, Simona
    Angelucci, Francesco
    Pavelek, Zbysek
    DRUGS IN R&D, 2023, 23 (04) : 331 - 338
  • [36] MRI techniques and cognitive impairment in the early phase of relapsing-remitting multiple sclerosis
    Zivadinov, R
    De Masi, R
    Nasuelli, D
    Bragadin, LM
    Ukmar, M
    Pozzi-Mucelli, RS
    Grop, A
    Cazzato, E
    Zorzon, M
    NEURORADIOLOGY, 2001, 43 (04) : 272 - 278
  • [37] Cognitive deficits in early relapsing-remitting multiple sclerosis
    Tinnefeld, M.
    Wilhelm, H.
    Daum, I.
    Faustmann, P. M.
    Haase, C. G.
    AKTUELLE NEUROLOGIE, 2008, 35 (01) : 2 - 7
  • [38] Treatment with alemtuzumab after fingolimod in relapsing-remitting multiple sclerosis is effective and safe
    Alcala, C.
    Gascon, F.
    Perez-Miralles, F.
    Dominguez, J. A.
    Garcia Gil-Perotin, S.
    Casanova, B.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 274 - 274
  • [39] Cardiac repolarization during fingolimod treatment in patients with relapsing-remitting multiple sclerosis
    Laiho, Aapo
    Laitinen, Tiina M.
    Hartikainen, Paivi
    Hartikainen, Juha E. K.
    Laitinen, Tomi P.
    Simula, Sakari
    BRAIN AND BEHAVIOR, 2018, 8 (02):
  • [40] Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
    Kuhle, Jens
    Disanto, Giulio
    Lorscheider, Johannes
    Stites, Tracy
    Chen, Yu
    Dahlke, Frank
    Francis, Gordon
    Shrinivasan, Anupama
    Radue, Ernst-Wilhelm
    Giovannoni, Gavin
    Kappos, Ludwig
    NEUROLOGY, 2015, 84 (16) : 1639 - 1643
12345